A vaccine from GlaxoSmithKline showed the potential to protect adults ages 50 to 59 from respiratory syncytial virus in a late-stage clinical trial, the company said Wednesday. The initial trial …
A doctor vaccinates an infant against respiratory syncytial virus (RSV) in a treatment room of her paediatric practice. Swen Pförtner | Picture Alliance | Getty Images The Centers for Disease …
Expectant parents could soon have another new option this fall to protect their newborns from RSV, or respiratory syncytial virus, the most common cause of hospitalization in American infants, after …
CFOTO | Future Publishing | Getty Images The Food and Drug Administration on Monday approved a vaccine from Pfizer that protects infants from respiratory syncytial virus, the leading cause of …
It may still feel like summer, but the fall is quickly approaching — along with the risk of seasonal viruses. On “CBS Mornings” Monday, Dr. Céline Gounder, a CBS News medical …
Many babies should get a shot soon after birth to protect them from RSV, or respiratory syncytial virus, a panel of the Centers for Disease Control and Prevention’s outside advisers …
Jun Li | Istock | Getty Images GlaxoSmithKline on Wednesday sued Pfizer in U.S. court, alleging patent infringement over Britain-based GSK’s respiratory syncytial virus vaccine. GSK claims New York-based Pfizer’s …
Budrul Chukrut | Lightrocket | Getty Images GlaxoSmithKline CEO Emma Walmsley on Wednesday said she expects uptake for the company’s new RSV vaccine to start off slower than it did …
The Food and Drug Administration announced Monday it had approved a new kind of immunization to protect babies from RSV, or respiratory syncytial virus. The drug, nirsevimab, is one of …
Respiratory syncytial virus vial. Manjurul | Istock | Getty Images The Centers for Disease Control and Prevention on Thursday recommended that adults ages 60 and above receive a single dose …